One card for instant savings

Plus product education and specialist support

Eligibility Requirements »

In order to activate your $0* Copay Card, you must meet the eligibility requirements:

Are you currently a resident of the United States or Puerto Rico?

Are your prescriptions paid for in part or in full under any state or federally funded program? Such programs include, but are not limited to, Medicare or Medicaid, Medigap, VA, DOD, or TriCare.

* Certain restrictions apply. For eligible patients with private health insurance, this card may cover the entire insurance copay or up to $300 of the cash price if you are not insured. For specific eligibility requirements and program restrictions, click here or call 1-888-203-1104. Each card is valid for up to 6 prescription fills for Taclonex® Topical Suspension.

*Patient First Name

*Patient Last Name

*Street Address

Street Address (cont.)

*City

*State

*Zip Code

*Patient Date of Birth

*Phone Number

*Preferred Method of Contact

Here is how LEO Pharma may use your personal information. We only use personal information for the reasons it was provided. We may disclose your personal information to third party service providers, but only the information needed for each service. We will notify you before we use or disclose your personal information for any other reason and you will have an opportunity to opt-out. We use commercially reasonable measures to protect personal information, but we assume no liability for its loss, misuse or unauthorized disclosure. If our business is sold, we will require the purchaser to honor our Privacy Policy. You may change or remove your personal information by calling 1-888-203-1104. For a copy of the LEO Pharma Privacy Policy click on the Privacy Link below. The information you provide, as well as the information obtained about you from the pharmacy, will be shared with the manufacturer and any companies working with the manufacturer.

Do you agree to the Taclonex® Copay Card Terms and Conditions and consent to use and disclosure of your personal information under the LEO Pharma Privacy Policy for the purpose of activating the Copay Card and providing administrative updates relating to the Copay Card?

LEO is offering a LEO QualityCare program to assist with any product-related questions. LEO QualityCare connects you to helpful specialists who can assist you during treatment. As part of the LEO QualityCare program, LEO may use your personal information to contact you via phone, e-mail, or mail.

Do you agree and consent to use and disclosure of your personal information under the LEO Pharma Privacy Policy for the purpose of enrolling in the LEO QualityCare program?

We would like to use your personal information to contact you to provide marketing information on LEO Pharma products, services, and programs, or to promote disease awareness. This marketing information could be sent to you via e-mail, telephone, or mail. Do you consent to the use and disclosure of your personal information under the LEO Pharma Privacy Policy for the purpose of providing this marketing information?

*Required fields are outlined in red

INDICATION AND USAGE

Taclonex® Topical Suspension is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 18 years and older and for plaque psoriasis of the scalp in patients 12 to 17 years. Apply Taclonex® Topical Suspension to affected areas once daily for up to 8 weeks. Therapy should be discontinued when control is achieved. Patients 18 years and older should not use more than 100 g per week and patients 12 to 17 years should not use more than 60 g per week.

IMPORTANT SAFETY INFORMATION

FOR TOPICAL USE ONLY. Taclonex® Topical Suspension is not for oral, ophthalmic, or intravaginal use and should not be applied to the face, axillae, or groin. Do not use if atrophy is present at the treatment site. Do not use with occlusive dressings unless directed by a physician.

Hypercalcemia and hypercalciuria have been observed with use of Taclonex®. If hypercalcemia or hypercalciuria develop, discontinue treatment until parameters of calcium metabolism have normalized. Taclonex® can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. Use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression and calcium abnormalities. If HPA axis suppression is documented, gradually withdraw the drug, reduce the frequency of application, or substitute with a less potent steroid. Cushing’s syndrome and hyperglycemia may also occur in adults due to the systemic effects of the topical corticosteroid. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of systemic toxicity, HPA axis suppression and adrenal insufficiency. Rare systemic toxicities such as Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients.

In clinical trials, the most common adverse reactions that occurred in 1% of subjects treated with Taclonex® and at a rate higher than in subjects treated with vehicle were folliculitis and burning sensation of skin. Other less common adverse reactions (<1% but >0.1%) were, in decreasing order of incidence: acne, exacerbation of psoriasis, eye irritation, and pustular rash. Local adverse reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform dermatitis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria and may be more likely with occlusive use or more potent corticosteroids.

Taclonex® may cause eye irritation. Avoid eye exposures. Patients who apply Taclonex® to exposed skin should avoid excessive exposure to either natural or artificial sunlight, including tanning booths, sun lamps, etc. There are no adequate and well-controlled studies of Taclonex® Topical Suspension in pregnant women. Taclonex® should be used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus. Because many drugs are excreted in human milk, caution should be exercised when Taclonex® Topical Suspension is administered to a nursing woman. The patient should be instructed not to use Taclonex® Topical Suspension on the breast when nursing. Safety and effectiveness of the use of Taclonex® Topical Suspension in pediatric patients under the age of 12 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please click here for full Prescribing Information

The health information contained on this Web site is provided for educational purposes only and is not intended to replace discussions with a healthcare professional. All decisions regarding patient care must be made with a healthcare professional.

This site is intended for US residents only. The products discussed on this site may have different product labeling in different countries.

Click here to view the complete Important Safety Information. »

INDICATION AND USAGE

Taclonex® Topical Suspension is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 18 years and older and for plaque psoriasis of the scalp in patients 12 to 17 years. Apply Taclonex® Topical Suspension to affected areas once daily for up to 8 weeks. Therapy should be discontinued when control is achieved. Patients 18 years and older should not use more than 100 g per week and patients 12 to 17 years should not use more than 60 g per week.

IMPORTANT SAFETY INFORMATION

FOR TOPICAL USE ONLY. Taclonex® Topical Suspension is not for oral, ophthalmic, or intravaginal use and should not be applied to the face, axillae, or groin. Do not use if atrophy is present at the treatment site. Do not use with occlusive dressings unless directed by a physician.

Hypercalcemia and hypercalciuria have been observed with use of Taclonex®. If hypercalcemia or hypercalciuria develop, discontinue treatment until parameters of calcium metabolism have normalized. Taclonex® can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. Use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression and calcium abnormalities. If HPA axis suppression is documented, gradually withdraw the drug, reduce the frequency of application, or substitute with a less potent steroid. Cushing’s syndrome and hyperglycemia may also occur in adults due to the systemic effects of the topical corticosteroid. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of systemic toxicity, HPA axis suppression and adrenal insufficiency. Rare systemic toxicities such as Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients.

In clinical trials, the most common adverse reactions that occurred in 1% of subjects treated with Taclonex® and at a rate higher than in subjects treated with vehicle were folliculitis and burning sensation of skin. Other less common adverse reactions (<1% but >0.1%) were, in decreasing order of incidence: acne, exacerbation of psoriasis, eye irritation, and pustular rash. Local adverse reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform dermatitis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria and may be more likely with occlusive use or more potent corticosteroids.

Taclonex® may cause eye irritation. Avoid eye exposures. Patients who apply Taclonex® to exposed skin should avoid excessive exposure to either natural or artificial sunlight, including tanning booths, sun lamps, etc. There are no adequate and well-controlled studies of Taclonex® Topical Suspension in pregnant women. Taclonex® should be used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus. Because many drugs are excreted in human milk, caution should be exercised when Taclonex® Topical Suspension is administered to a nursing woman. The patient should be instructed not to use Taclonex® Topical Suspension on the breast when nursing. Safety and effectiveness of the use of Taclonex® Topical Suspension in pediatric patients under the age of 12 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please click here for full Prescribing Information

The health information contained on this Web site is provided for educational purposes only and is not intended to replace discussions with a healthcare professional. All decisions regarding patient care must be made with a healthcare professional.

This site is intended for US residents only. The products discussed on this site may have different product labeling in different countries.